0000899243-19-016474.txt : 20190611
0000899243-19-016474.hdr.sgml : 20190611
20190611183149
ACCESSION NUMBER: 0000899243-19-016474
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190607
FILED AS OF DATE: 20190611
DATE AS OF CHANGE: 20190611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BREITMEYER JAMES B
CENTRAL INDEX KEY: 0001244823
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50549
FILM NUMBER: 19892094
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GTX INC /DE/
CENTRAL INDEX KEY: 0001260990
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 621715807
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 17 W PONTOTOC AVE.
STREET 2: SUITE 100
CITY: MEMPHIS
STATE: TN
ZIP: 38103
BUSINESS PHONE: 901-523-9700
MAIL ADDRESS:
STREET 1: 17 W PONTOTOC AVE.
STREET 2: SUITE 100
CITY: MEMPHIS
STATE: TN
ZIP: 38103
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-06-07
0
0001260990
GTX INC /DE/
ONCT
0001244823
BREITMEYER JAMES B
C/O ONCTERNAL THERAPEUTICS, INC.
12230 EL CAMINO REAL, SUITE 300
SAN DIEGO
CA
92130
1
1
0
0
President, CEO
Common Stock
2019-06-07
4
A
0
255591
A
255591
D
Common Stock
2019-06-07
4
A
0
733
A
733
I
By child.
Common Stock
2019-06-07
4
A
0
21544
A
21544
I
By family trust.
Stock Options
0.68
2019-06-07
4
A
0
117417
A
2025-08-30
Common Stock
117417
117417
D
Stock Options
0.68
2019-06-07
4
A
0
1467
A
2027-04-12
Common Stock
1467
1467
I
By spouse.
Warrants
6.13
2019-06-07
4
A
0
733
A
2022-09-12
Common Stock
733
733
I
By family trust.
Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the "Merger Agreement"), by and among Oncternal Therapeutics, Inc. ("Old Oncternal"), GTx, Inc. ("GTx") and certain of their subsidiaries, on June 7, 2019 (the "Effective Time"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share.
The option is currently vested with respect to 110,079 shares. The remaining shares subject to the option will vest in three equal monthly installments beginning on June 30, 2019.
The option is currently vested with respect to 826 shares. The remaining shares subject to the option will vest in equal monthly installments until February 1, 2021.
The warrants are currently exercisable.
/s/ Hazel M. Aker, Attorney-in-fact
2019-06-11